{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03911739",
            "orgStudyIdInfo": {
                "id": "2019-0429-3"
            },
            "secondaryIdInfos": [
                {
                    "id": "UG1DA013732",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/UG1DA013732"
                }
            ],
            "organization": {
                "fullName": "University of Cincinnati",
                "class": "OTHER"
            },
            "briefTitle": "Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study",
            "officialTitle": "NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): Infant Neurodevelopmental Outcomes (INO) Sub-study",
            "acronym": "MOMs-INO",
            "therapeuticArea": [
                "Women's Health",
                "Rare Diseases",
                "Other"
            ],
            "study": "medication-treatment-for-opioid-use-disorder-in-expectant-mothers-infant-neurodevelopmental-outcomes-sub-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-06-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-01-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-04-09",
            "studyFirstSubmitQcDate": "2019-04-09",
            "studyFirstPostDateStruct": {
                "date": "2019-04-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-25",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "T. John Winhusen, PhD",
                "investigatorTitle": "Professor; Vice Chair and Division Director of Addiction Sciences",
                "investigatorAffiliation": "University of Cincinnati"
            },
            "leadSponsor": {
                "name": "T. John Winhusen, PhD",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                },
                {
                    "name": "The Emmes Company, LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1). Caretakers of the infants delivered by MOMs participants will be offered the opportunity to enroll in this sub-study, which is designed to evaluate the impact of extended-release buprenorphine (BUP-XR), relative to sublingual buprenorphine (BUP-SL), on infant neurodevelopment. The additional data collected in this sub-study will be combined with data from the main MOMs trial."
        },
        "conditionsModule": {
            "conditions": [
                "Opioid-Related Disorders",
                "Drug Addiction",
                "Pregnancy Related",
                "Substance Abuse",
                "Drug Abuse",
                "Neonatal Abstinence Syndrome",
                "Neonatal Opiate Withdrawal Syndrome",
                "Drug Abuse in Pregnancy"
            ],
            "keywords": [
                "CTN-0080",
                "clinical trials network",
                "medication assisted treatment",
                "pharmacokinetics"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "BUP-XR",
                    "type": "EXPERIMENTAL",
                    "description": "Weekly subcutaneous Buprenorphine Injection (CAM2038) during pregnancy. During the 12-month postpartum phase, participants who are breastfeeding will continue receiving subcutaneous Buprenorphine Injection weekly; participants who are not breastfeeding will receive subcutaneous Buprenorphine Injection monthly.\n\nThe target doses will be 24 mg for the weekly formulation and 96 mg for the monthly formulation, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.).",
                    "interventionNames": [
                        "Drug: Buprenorphine Injection"
                    ]
                },
                {
                    "label": "BUP-SL",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Daily sublingual buprenorphine, with or without naloxone, based on site preference, during pregnancy and during the 12-month postpartum phase.\n\nThe target dose will be 16 mg daily, but the actual dose may be lower or higher as determined by the prescribing clinician (e.g., based on craving/withdrawal experienced by the participant, etc.).",
                    "interventionNames": [
                        "Drug: Buprenorphine Sublingual Product"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Buprenorphine Injection",
                    "description": "Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).",
                    "armGroupLabels": [
                        "BUP-XR"
                    ],
                    "otherNames": [
                        "CAM2038"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Buprenorphine Sublingual Product",
                    "description": "Sublingual buprenorphine (BUP-SL), administered daily.",
                    "armGroupLabels": [
                        "BUP-SL"
                    ],
                    "otherNames": [
                        "Subutex",
                        "Suboxone"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Bayley Scales of Infant Development",
                    "description": "The Bayley Scales of Infant Development is considered the gold standard assessment of early child development and includes cognitive, language, fine motor, and gross motor subscales. Subscale scores each range from 1 - 19, with higher scores indicating higher performance.",
                    "timeFrame": "24 months post-partum"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Bayley Scales of Infant Development",
                    "description": "The Bayley Scales of Infant Development is considered the gold standard assessment of early child development and includes cognitive, language, fine motor, and gross motor subscales. Subscale scores each range from 1 - 19, with higher scores indicating higher performance.",
                    "timeFrame": "12 months post-partum"
                },
                {
                    "measure": "Child Behavior Checklist",
                    "description": "The Child Behavior Checklist includes items that describe behavioral, emotional, and social problems that characterize preschool children.",
                    "timeFrame": "24 months post-partum"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* The participant must be the caretaker of an infant that was delivered as part of the MOMs trial (Unique protocol ID: 2019-0429-1).\n\nExclusion Criteria:\n\n-",
            "healthyVolunteers": false,
            "sex": "ALL",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Frankie Kropp, MS",
                    "role": "CONTACT",
                    "phone": "513-585-8290",
                    "email": "kroppfb@ucmail.uc.edu"
                },
                {
                    "name": "Ben Kropp, MSLS",
                    "role": "CONTACT",
                    "phone": "513-585-8287",
                    "email": "kroppbn@ucmail.uc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "T. John Winhusen, PhD",
                    "affiliation": "University of Cincinnati",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Zuckerberg San Francisco General",
                    "status": "WITHDRAWN",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Gateway Community Services",
                    "status": "RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32204",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "Massachusetts General Hospital HOPE Clinic",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Boston Medical Center",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02118",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "University of New Mexico Milagro Clinic",
                    "status": "WITHDRAWN",
                    "city": "Albuquerque",
                    "state": "New Mexico",
                    "zip": "87106",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.08449,
                        "lon": -106.65114
                    }
                },
                {
                    "facility": "University of Cincinnati Health Perinatal Addictions Program",
                    "status": "WITHDRAWN",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "CODA, Inc.",
                    "status": "COMPLETED",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97214",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Pregnancy Recovery Center at Magee-Womens Hospital of UPMC",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15213",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Medical University of South Carolina",
                    "status": "RECRUITING",
                    "city": "Charleston",
                    "state": "South Carolina",
                    "zip": "29425",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.77657,
                        "lon": -79.93092
                    }
                },
                {
                    "facility": "Vanderbilt University Medical Center",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "University of Utah SUPeRAD Clinic",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84108",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "Addiction Recovery Services (ARS), Swedish Medical Center",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98107",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "Marshall Health MARC Program",
                    "status": "RECRUITING",
                    "city": "Huntington",
                    "state": "West Virginia",
                    "zip": "25701",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.41925,
                        "lon": -82.44515
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Data will be transmitted by the study Data and Statistics Center to the designated party for de-identification, posting, storing, and archiving on NIDA's Data Share website. Data Share is an online repository of data from studies funded by the National Institute on Drug Abuse. All de-identified individual participant data is expected to be made available.",
            "infoTypes": [
                "STUDY_PROTOCOL"
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009357",
                    "term": "Neonatal Abstinence Syndrome"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                },
                {
                    "id": "D000009293",
                    "term": "Opioid-Related Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000013375",
                    "term": "Substance Withdrawal Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000079524",
                    "term": "Narcotic-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000007232",
                    "term": "Infant, Newborn, Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12244",
                    "name": "Opioid-Related Disorders",
                    "asFound": "Opioid-Related Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19100",
                    "name": "Behavior, Addictive",
                    "relevance": "LOW"
                },
                {
                    "id": "M16162",
                    "name": "Substance Withdrawal Syndrome",
                    "asFound": "Withdrawal Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12302",
                    "name": "Neonatal Abstinence Syndrome",
                    "asFound": "Neonatal Abstinence Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "asFound": "Drug Abuse",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2057",
                    "name": "Narcotic-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10276",
                    "name": "Infant, Newborn, Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002047",
                    "term": "Buprenorphine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000701",
                    "term": "Analgesics, Opioid"
                },
                {
                    "id": "D000009294",
                    "term": "Narcotics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000009292",
                    "term": "Narcotic Antagonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M5317",
                    "name": "Buprenorphine",
                    "asFound": "Attention",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12221",
                    "name": "Naloxone",
                    "relevance": "LOW"
                },
                {
                    "id": "M447",
                    "name": "Buprenorphine, Naloxone Drug Combination",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12243",
                    "name": "Narcotic Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "NarcAntag",
                    "name": "Narcotic Antagonists"
                }
            ]
        }
    },
    "hasResults": false
}